All In Biotech

Drug Trial Radar · NCT07218380

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined With Enfortumab Vedotin and Pembrolizumab in Adults With Untreated Locally Advanced or Metastatic Urothelial Carcinoma With an FGFR3 Genetic Alteration

Last checked: Nov 20, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 450 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

450

Planned (sponsor's estimate)

Start

Dec 12, 2025

Primary completion

Oct 2029

Study completion May 2033

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Oct 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread. Vepugratinib or placebo will be administered in combination with enfortumab vedotin and pembrolizumab. Study participation could last up to approximately 6 years.

Conditions

  • Carcinoma, Transitional Cell
  • Urinary Bladder Neoplasms
  • Neoplasm Metastasis

Interventions

  • VepugratinibDrug

    Administered orally

  • PlaceboOther

    Administered orally

  • EVDrug

    Administered by IV infusion

  • PembrolizumabDrug

    Administered by IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-related adverse events related to vepugratinib in combination with EV and pembrolizumabTime frame: From baseline up to 90 months
  2. Safety Lead-in: Overall Response Rate (ORR)Time frame: From baseline up to 90 months
  3. Progression-free Survival (PFS)Time frame: Baseline to Study Completion (estimated as 6 years)

Locations

276 sites in 19 countries. Site status is shown where the registry gives one.

  • The University of Arizona Cancer Center - North Campus

    Tucson, Arizona · Recruiting

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas · Not yet recruiting

  • Chao Family Comprehensive Cancer Center and Ambulatory Care (CIACC) - Irvine

    Irvine, California · Recruiting

  • TRIO-US (Translational Research in Oncology-US)

    Los Angeles, California · Recruiting

  • UCLA Hematology/Oncology - Santa Monica

    Los Angeles, California · Recruiting

  • University of California, Irvine (UCI) Health - UC Irvine Medical Center

    Orange, California · Recruiting

  • University of California Davis (UC Davis) Comprehensive Cancer Center

    Sacramento, California · Recruiting

  • UCSF Medical Center at Mission Bay

    San Francisco, California · Recruiting

  • Hunt Cancer Institute, an Affiliate of Cedars-Sinai Cancer (TMPN)

    Torrance, California · Recruiting

  • AdventHealth Medical Group - Porter

    Denver, Colorado · Not yet recruiting

  • Colorado West Healthcare System - Grand Valley Oncology

    Grand Junction, Colorado · Recruiting

  • Yale-New Haven Hospital

    New Haven, Connecticut · Not yet recruiting

  • MedStar Washington Hospital Center

    Washington D.C., District of Columbia · Not yet recruiting

  • AdventHealth Orlando

    Orlando, Florida · Not yet recruiting

  • St. Luke's Cancer Institute: Boise

    Boise, Idaho · Not yet recruiting

  • University of Illinois at Chicago

    Chicago, Illinois · Recruiting

  • University of Chicago Medical Center

    Chicago, Illinois · Not yet recruiting

  • Endeavor Health

    Evanston, Illinois · Not yet recruiting

  • Accellacare of Duly

    Lisle, Illinois · Not yet recruiting

  • Parkview Research Center at Parkview Regional Medical Center

    Fort Wayne, Indiana · Recruiting

  • Indiana University Melvin and Bren Simon Cancer Center

    Indianapolis, Indiana · Recruiting

  • Franciscan Health

    Indianapolis, Indiana · Recruiting

  • University of Kentucky Chandler Medical Center

    Lexington, Kentucky · Suspended

  • Mary Bird Perkins Cancer Center

    Baton Rouge, Louisiana · Recruiting

  • Mary Bird Perkins Cancer Center - Metairie

    Metairie, Louisiana · Recruiting

  • Ochsner Clinic Foundation

    New Orleans, Louisiana · Not yet recruiting

  • Johns Hopkins Hospital

    Baltimore, Maryland · Recruiting

  • James M Stockman Cancer Institute

    Frederick, Maryland · Not yet recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Not yet recruiting

  • University of Massachusetts Medical School

    Worcester, Massachusetts · Not yet recruiting

  • Karmanos Cancer Institute

    Detroit, Michigan · Recruiting

  • Brigitte Harris Cancer Pavilion

    Detroit, Michigan · Not yet recruiting

  • Oncology Hematology Associates

    Springfield, Missouri · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada · Recruiting

  • Astera Cancer Care

    East Brunswick, New Jersey · Recruiting

  • Columbia University Irving Medical Center

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Weill Cornell Medical College

    New York, New York · Not yet recruiting

  • Wilmot Cancer Institute

    Rochester, New York · Not yet recruiting

Showing 40 of 276 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.